AtaiBeckley Inc.

ATAI

Precision medicineBiotech & pharmaceuticals

$7.38vs prev close▼-0.04(-0.54%)

$3.2752W Range$7.45

98% from low

+0.20 (+2.79%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

9 sells

Consecutive sells

1M net buy

-$11.7M

≈ -1.6M shares

Portfolio Weight

0.07%

1M -0.09%p

Holding ETFs

1 ETFs

ARKG

Sell · Weight Down

ARK net-sold the stock and the price fell, decreasing its portfolio weight.

Shares -72.4% · Market value -59.9% · Weight -0.09%p

Trade Intensity

Concentrated sells

Basis: 9 sells · 0 buys in 1M

Trade Log9-day SELL streak

Date	Action	ETF	Shares	Close	Est. total
26.08.20	SELL	ARKG	360	$7.42	$2.7K
26.08.19	SELL	ARKG	2,670	$7.36	$19.7K
26.08.18	SELL	ARKG	20,847	$7.29	$152.0K
26.08.17	SELL	ARKG	226,381	$7.24	$1.6M
26.08.13	SELL	ARKG	241,388	$7.25	$1.8M
26.08.07	SELL	ARKG	158,334	$7.25	$1.1M
26.08.06	SELL	ARKG	516,184	$7.18	$3.7M
26.08.05	SELL	ARKG	181,001	$7.22	$1.3M
26.08.04	SELL	ARKG	275,338	$7.18	$2.0M
26.07.24	SELL	ARKG	758,353	$7.18	$5.4M
26.07.20	SELL	ARKG	719,543	$7.19	$5.2M
26.07.17	SELL	ARKG	70,667	$7.22	$510.2K
26.07.16	SELL	ARKG	1,123,010	$7.15	$8.0M
26.03.03	BUY	ARKG	640,324	$3.69	$2.4M
26.02.26	BUY	ARKG	482,407	$3.73	$1.8M

08.20SELL

360

ARKGClose$7.42Est. total$2.7K

08.19SELL

2,670

ARKGClose$7.36Est. total$19.7K

08.18SELL

20,847

ARKGClose$7.29Est. total$152.0K

08.17SELL

226,381

ARKGClose$7.24Est. total$1.6M

08.13SELL

241,388

ARKGClose$7.25Est. total$1.8M

08.07SELL

158,334

ARKGClose$7.25Est. total$1.1M

08.06SELL

516,184

ARKGClose$7.18Est. total$3.7M

08.05SELL

181,001

ARKGClose$7.22Est. total$1.3M

08.04SELL

275,338

ARKGClose$7.18Est. total$2.0M

07.24SELL

758,353

ARKGClose$7.18Est. total$5.4M

07.20SELL

719,543

ARKGClose$7.19Est. total$5.2M

07.17SELL

70,667

ARKGClose$7.22Est. total$510.2K

07.16SELL

1,123,010

ARKGClose$7.15Est. total$8.0M

03.03BUY

640,324

ARKGClose$3.69Est. total$2.4M

02.26BUY

482,407

ARKGClose$3.73Est. total$1.8M

1 / 3

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

1,182,883

Portfolio Weight

0.07%

in ETF 0.51%

Est. Value

$9M

30D Net

-$31M

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Hold

Buy

Hold

Analyst Targets

avg.

$8.10

vs Current ▲ +9.8% upside

Current$7.38

Low ~ High$7.45 ~ $9.25

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Deutsche Bank

Hold

$8.00

+8.40%

—

Downgrade

2026-08-12

HC Wainwright & Co.

Neutral

$7.50

+1.63%

—

Downgrade

2026-07-20

Guggenheim

Neutral

N/A

—

Downgrade

2026-07-17

Jones Trading

Hold

N/A

—

Downgrade

2026-07-17

Jefferies

Hold

$7.50

+1.63%

—

Downgrade

2026-07-17

1 / 4

Avg Target

$8.10

vs Current ▲ +9.8% upside

Hold

14 analysts

Buy 1Hold 13

Low $7.45

Current $7.38

High $9.25

Firm	Position	Target	Upside	Close	Action	Date
Deutsche Bank	Hold	$8.00	+8.40%	—	Downgrade	26.08.12
HC Wainwright & Co.	Neutral	$7.50	+1.63%	—	Downgrade	26.07.20
Guggenheim	Neutral	N/A	N/A	—	Downgrade	26.07.17
Jones Trading	Hold	N/A	N/A	—	Downgrade	26.07.17
Jefferies	Hold	$7.50	+1.63%	—	Downgrade	26.07.17

1 / 4

Price Information

Previous Close$7.42

Open$7.40

Day Range$7.38 - $7.45

52-Week Range$3.27 - $7.45

1-Year Change55.70%

Trading Volume

Volume4,307,646

Avg Volume (3mo)12,034,096

Valuation

Market Cap2.7B

Book Value$0.48

Shares Outstanding370,864,669

Financials

Revenue (TTM)4.5M

Net Income-668,193,024

EPS$-2.79

EBITDA-140,791,008

Profitability

P/E Ratio-

P/B Ratio15.44

Return on Equity (ROE)-417.21%

Return on Assets (ROA)-39.03%

Profit Margin0.00%

EV/EBITDA-17.87

Beta1.55

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)70.83

Company Overview

AtaiBeckley Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for mental health conditions. Their pipeline includes compounds like BPL-003, RL-007, and ELE-101, targeting conditions such as treatment-resistant depression, alcohol use disorder, and cognitive impairment associated with schizophrenia. The company is actively conducting clinical trials across the US, Germany, and Canada for these innovative therapies.

P/B

15.44

High valuation

ROE

-417.2%

Persistent loss

Beta

1.55

High volatility

RSI(14)

70.8

Overbought

AI-generated summary. Not investment advice.

AtaiBeckley Inc.

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks